Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome  

Oleh:

de Paula Guedes Neto, Ernesto ; Savaris, Ricardo Francalacci ; von Eye Corleta, Helena ; de Moraes, Gisele Silva

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Fertility and Sterility (keterangan: ada di ClinicalKey) vol. 96 no. 03 (Sep. 2011), page 769-773.
Topik: Clomiphene citrate; ovulation; polycystic ovary syndrome; progesterone; raloxifene; ultrasound

Ketersediaan

Perpustakaan FK Nomor Panggil: F02.K.2011.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Objective To compare the ovulation rate between raloxifene and clomiphene citrate (CC) in patients with polycystic ovary syndrome (PCOS). Design Double-blind, randomized, superiority clinical trial. Setting Tertiary university hospital. Patient(s) Women with ovulatory dysfunction and PCOS based on the Rotterdam criteria. Intervention(s) One of two oral treatments: 5 days of 100 mg/day of CC or R. Main Outcome Measure(s) Ovulation, based on follicle collapse on serial ultrasound and midsecretory serum progesterone concentration (=3 ng/dL). Result(s) The women with PCOS (n = 82) were randomized to receive CC (n = 40) or raloxifene (n = 42). From these, 68 patients finished the trial according to the protocol (CC: n = 37; raloxifene: n = 31). There were no statistically significant differences between the groups in ovulation rates per an intention-to-treat analysis based on ultrasound alone (CC: 21 of 40 vs. raloxifene: 17 of 42) or on progesterone levels (CC: 16 of 40 vs. raloxifene: 11 of 42). No serious adverse events were observed in either group. Conclusion(s) No statistically significant difference in ovulation was observed between raloxifene and clomiphene citrate in patients with PCOS with ovulatory dysfunction.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali